Targeting the gastrointestinal tract to treat type 2 diabetes (Q26738730)

Bariatric surgery: a systematic review and meta-analysis

Europe PubMed Central

title

Targeting the gastrointestinal tract to treat type 2 diabetes (English)

0 references

0 references

Paige V Bauer

1

0 references

Frank A Duca

series ordinal

2

0 references

language of work or name

English

0 references

publication date

September 2016

0 references

published in

Journal of Endocrinology

0 references

volume

230

0 references

page(s)

R95-R113

0 references

issue

3

0 references

cites work

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Bilio-pancreatic bypass for obesity: II. Initial experience in man

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Surgical control of obesity and diabetes: the role of intestinal vs. gastric mechanisms in the regulation of body weight and glucose homeostasis

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Surgical treatment of nonseverely obese patients with type 2 diabetes mellitus: sleeve gastrectomy with ileal transposition (SGIT) is the same as the neuroendocrine brake (NEB) procedure or ileal interposition associated with sleeve gastrectomy (II-S

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effects of duodeno-jejunal bypass on glucose metabolism in obese rats with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Laparoscopic sleeve gastrectomy with duodenojejunal bypass: technique and preliminary results

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Early changes in incretin secretion after laparoscopic duodenal-jejunal bypass surgery in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)?

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Laparoscopic single-anastomosis duodenal-jejunal bypass with sleeve gastrectomy (SADJB-SG): short-term result and comparison with gastric bypass

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Long-Term Metabolic Outcomes 5 to 20 Years After Biliopancreatic Diversion

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

FGF 19 and Bile Acids Increase Following Roux-en-Y Gastric Bypass but Not After Medical Management in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Duodenojejunal Bypass Leads to Altered Gut Microbiota and Strengthened Epithelial Barriers in Rats

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

How to Choose the Best Metabolic Procedure?

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Glucose sensing in L cells: a primary cell study

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Intestinal cholecystokinin controls glucose production through a neuronal network

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

TGR5-mediated bile acid sensing controls glucose homeostasis

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Jejunal leptin-PI3K signaling lowers glucose production.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Metformin: from mechanisms of action to therapies

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Surgical treatment of obesity

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Oleic acid stimulates glucagon-like peptide-1 release from enteroendocrine cells by modulating cell respiration and glycolysis

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Deletion of leptin signaling in vagal afferent neurons results in hyperphagia and obesity

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gut fat sensing in the negative feedback control of energy balance--recent advances

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Diabetes remission without weight loss after duodenal bypass surgery

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Systematic ileal transposition in Zucker rats shows advantage for long segment distal transposition

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

GPR119 as a fat sensor

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

https://api.crossref.org/works/10.1530%2FJOE-16-0056

1 reference

7 January 2021

Ileal transposition surgery produces ileal length-dependent changes in food intake, body weight, gut hormones and glucose metabolism in rats.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

FXR is a molecular target for the effects of vertical sleeve gastrectomy

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Targeting bile-acid signalling for metabolic diseases

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Oligofructose promotes satiety in healthy human: a pilot study

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Entry of exendin-4 into brain is rapid but may be limited at high doses

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Duodenal mucosal protein kinase C-δ regulates glucose production in rats

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Duodenal activation of cAMP-dependent protein kinase induces vagal afferent firing and lowers glucose production in rats

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The effects of vertical sleeve gastrectomy in rodents are ghrelin independent

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Bariatric surgery versus conventional medical therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Human gut microbiota in obesity and after gastric bypass

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Activation of Short and Long Chain Fatty Acid Sensing Machinery in the Ileum Lowers Glucose Production in Vivo

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Hormonal signaling in the gut.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effect of fat replacement by inulin or lupin-kernel fibre on sausage patty acceptability, post-meal perceptions of satiety and food intake in men.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Early resolution of type 2 diabetes seen after Roux-en-Y gastric bypass and vertical sleeve gastrectomy

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Fermentable and Nonfermentable Fiber Supplements Did Not Alter Hunger, Satiety or Body Weight in a Pilot Study of Men and Women Consuming Self-Selected Diets

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Activation of vagal afferents in the rat duodenum by protein digests requires PepT1.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

CD36-dependent signaling mediates fatty acid-induced gut release of secretin and cholecystokinin

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The entire small intestine mediates the changes in glucose homeostasis after intestinal surgery in Goto-Kakizaki rats.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gut microbiota, nutrient sensing and energy balance

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Microbiota and diabetes: an evolving relationship.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Role of fatty acid transport protein 4 in oleic acid-induced glucagon-like peptide-1 secretion from murine intestinal L cells

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The extracellular calcium-sensing receptor is required for cholecystokinin secretion in response to L-phenylalanine in acutely isolated intestinal I cells

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Low-affinity CCK-A receptors are coexpressed with leptin receptors in rat nodose ganglia: implications for leptin as a regulator of short-term satiety

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Intestinal sweet-sensing pathways and metabolic changes after Roux-en-Y gastric bypass surgery.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Proglucagon-derived peptides: mechanisms of action and therapeutic potential

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Farnesoid X receptor is essential for normal glucose homeostasis

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

FGF19 action in the brain induces insulin-independent glucose lowering

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gut chemosensing mechanisms

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Metformin: an old but still the best treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Regulation of cholecystokinin secretion by peptones and peptidomimetic antibiotics in STC-1 cells

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

AMPK in the small intestine in normal and pathophysiological conditions.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

An Analysis of Cosecretion and Coexpression of Gut Hormones From Male Rat Proximal and Distal Small Intestine

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Identification and localization of glucagon-like peptide-1 and its receptor in rat brain.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Resolution of diabetes mellitus by ileal transposition compared with biliopancreatic diversion in a nonobese animal model of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Mechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Duodenal PKC-δ and cholecystokinin signaling axis regulates glucose production.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Molecular mechanisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Evaluation of the Effect of Enteral Lipid Sensing on Endogenous Glucose Production in Humans.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans - towards treatment with probiotics

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Probiotics as Complementary Treatment for Metabolic Disorders

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1530%2FJOE-16-0056

7 January 2021